Progress in the treatment of advanced and metastatic gastrointestinal stromal tumor
10.12354/j.issn.1000-8179.2024.20240587
- VernacularTitle:晚期或转移性胃肠道间质瘤治疗进展
- Author:
Peng QIUFENG
1
;
Luo SHIQIAO
Author Information
1. 重庆医科大学附属第一医院肝胆外科(重庆市 400016)
- Keywords:
advanced;
metastatic;
gastrointestinal stromal tumor(GIST);
treatment
- From:
Chinese Journal of Clinical Oncology
2024;51(14):742-747
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors(GISTs)are the most common mesenchymal tumors of the gastrointestinal tract.Extensive het-erogeneity exists in the clinical course and prognosis of GISTs due to multiple genetic mutations.Since the advent of tyrosine kinase inhibit-ors(TKIs),such as imatinib,the survival of patients with GISTs has substsntially improved.However,progression or metastasis often occurs in these patients.For advanced and metastatic GISTs,drug selection and surgical indications have been studied and debated in recent years.With further research in etiology and TKI resistance,novel target agents such as ripretinib,avapritinib,and other pathway inhibitors have been introduced into clinical practice,enabling a more individualized and accurate treatment modality for advanced and metastatic GISTs.This review provides an update on the current therapeutic development landscape in advanced and metastatic GISTs.
